We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Status: Active

Jun 16th 2020 - Jul 16th 2020

14 days left

Imagen is a company that has developed an automated, sophisticated algorithmic technique, PredictRx, to find the right treatment for any cancer type. Imagen collects the cancer samples from a patient, grows it in its specialised growth medium, and then subjects the medium to an automated fluorescence microscopy screening to measure drug responses on live tumour cells. The company's AI-powered biobank of over 150,000 drug responses then gives the best possible cancer treatment options, allowing the company to expand in the pharmaceutical sector by satisfying its unmet demand for patient-derived cancer models. Imgen requires investment to scale its infrastructure to create the world's leading 'Biobank' of clinically relevant patient-derived cancer models whilst building the most comprehensive big data set available in cancer research.

read more read less

Imagen Rating Review

Rated on 22/06/2020

Pitch Rated

79%

overall

Management

90%

Product

76%

Investment

72%

Pitch rating powered by CROWDRATING

What the ratings mean

  • 49% and under
    We suggest potential investors carry out further study of their own
    50-64%
    Room for improvement
    65-79%
    Worth considering
    80%+
    Gold rating, our highest rating
Click here for more information on our ratings
Login to view the full report

Management 90%

Skills 91%
Imagen has an experienced senior management team with nine full-time team members. The CEO of the company is a successful business leader and passionate about delivering value to patients, clients, and shareholders. He is skilled in biotechnology, business strategy, pharmaceutical sales, and oncology. The Chief Scientific Officer/Co-Founder has expertise in stem cells, translational research, cancer research, 3D cellular models, signal transduction, and toxicology. The business is also overseen by the Director of Business Development who is an expert in building the brand with his skills in sales management, biotechnology, business planning, team building, and new business development. It was noted that The company has outsourced finance through Alantra Corporate Finance LLP.


0 comments

Log in to comment


Funding progress



More from Medical

Span Health is a digital care platform that aims to help people avoid lifestyle-induced diseases, symptoms, medication, and complications. The company has helped more than 10,000 people to live a better and longer life. Span Health's easy-to-use mobile application allows patients to chat with clinicians, order blood tests at home, book video consultations, and see results in the application itself. Moreover, in 2019, the company agreed on a National Health Service (NHS) pilot test for 100 patients in collaboration with the National Institute of Health Research in North West London. Span Health will use the investment to provide employees with blood tests to screen for health risk factors and recover from detected illness safely and sustainably, improve its platform data insights, prediction and machine learning to better structure the clinician's processes, and further reduce its operational costs.
pledged: 106% days to go: 37 investment: £105,886
Tourniglo is a company that has come up with a unique two in one emergency tourniquet with a built-in torch. The innovation was driven by an identified need within the emergency services to provide an immediately available light source in dim-lighted areas when undertaking a patient or casualty eye examination as well as for military and close protection staff who might need to inject intravenous medication in rural areas. The global tourniquet systems market is expected to reach half a billion US dollars by 2025. The company aims to launch the production of its first product. Additionally, Tourniglo has been featured on the BBC website and has won various medals at international events, including a 'Gold Medal' at the World Invention Awards. The company requires investment to set-up manufacturing, packaging and distribution, and grow sales for the first year of commercialisation.
pledged: 31% days to go: 17 investment: £28,348
Accunea is the world’s first real-time continuous organ function monitoring company, specializing in biomarkers for kidney transplantation. Targeting NHS hospitals in the UK undertaking renal transplantation, the company aims to provide relief to patients awaiting organ transplants by ensuring availability of more organs for transplant and reducing the numbers of deaths due to increasing waiting list times. For this purpose, the company has designed a miniature analysis device which constantly monitors markers of kidney function and metabolism through a standard dribble line put into the vein of a patient. Accunea is raising £400,000 at a pre-money valuation of £2,230,000. The funds will be used to achieve clinical utility in Kidney and Pancreas.

Pitch Rated

71%

Overall

rating powered by

CROWD RATING™

pledged: 97% days to go: 31 investment: £388,038
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics. Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
pledged: 0% days to go: 29 investment: Withheld

  • £742,958
    pledged
  • 124%
    of goal

    £600,000
    target

    £10,620,474
    pre-money valuation

    5.35%
    equity available

    486
    investors

    £1,529
    pledge per investor

    06373341
    company number

    Active
    company status

    17/09/2007
    incorporated 13 years

    £6.33
    share price

    Equity Calculator
    Investment
    £
    Equity
    %
    Funding rounds
    16 Jun 20 Crowdcube £742,958 / 124% 79.33%
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph